中东和非洲人工血液替代品市场 – 行业趋势和 2028 年预测

市场分析与洞察：中东和非洲人工血液替代品市场

预计人工血液替代品市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场以 23.7% 的复合年增长率增长，预计到 2028 年将达到 1,966.01 万美元。新鲜血液的供应有限及其短暂的寿命，再加上对输血的需求不断增加以及对血液替代品开发资金的增加，成为人工血液替代品市场增长的驱动力。

人工血液替代品又称为氧疗法或血红蛋白氧载体。它用于模拟生物血液的功能，并提供输血替代品。人工血液是替代库存红细胞输血的解决方案，旨在克服血液供应不足、高风险污染、交叉配血要求等局限性。同种异体输血具有多重风险，可导致传染病传播、输血反应、输血相关急性肺损伤、术后伤口愈合延迟、免疫调节和癌症复发的潜在风险。它为新的、重要的救命医疗方法带来了希望。

Artificial blood are produced from sources such as animal blood, human blood, microorganisms recombinant Hb, stem cells and others. Artificial blood also offers several advantages over the human blood as it belongs to universal blood group and can be given to the patients regardless of their blood type. Also artificial blood substitutes don’t produce any immulogical reactions. Also, artificial blood substitute eliminates the risk of infectious diseases or contamination during transfusion and offers extended shelf life in comparision to the human blood as it can be stored for 3 years at room temperature or more while the human blood shelf life is short for 42 days. Artificial blood can be used for emergency situations and can be stored easily also is the perfect option for the patients who doesn’t accept blood from donors due to their religious beliefs.

Limited availability of fresh blood and its short life span coupled with increasing demand for blood transfusion and increased funding for development of blood substitutes are the key factors driving the Middle East & Africa artificial blood substitutes market. However, the high cost production of artificial blood as well as stringent rules laid down by governmental bodies for approval of blood substitute products may hamper the growth of the artificial blood substitutes market. Also, rising awareness regarding the advantages offered by artificial blood and rising demand for artificial blood coupled with insufficient number of blood donor and growing number of research and development on artificial blood will create huge opportunities for the Middle East & Africa artificial blood substitutes market. The in availability of artificial blood products, extended clinical trials and side effects associated with artificial blood will create a huge challenge for the Middle East & Africa artificial blood substitutes market.

The artificial blood substitutes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the artificial blood substitutes market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Artificial blood substitutes Market Scope and Market Size

The artificial blood substitutes market is segmented on the based on the product type, source, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of product type, the Middle East & Africa artificial blood substitutes market is segmented into perflurocarbon (PFCs) and hemoglobin-based oxygen carries (HBOCs). Perflurocarbon (PFCs) is further segmented into perftoran. Hemoglobin-based oxygen carries (HBOCs) is further segmented into oxyglobin and hemopure. In 2021, the hemoglobin-based oxygen carries (HBOCs) segment is expected to dominate the artificial blood substitutes market due to rising demand for blood sustitutes which eliminates the blood typing and to overcome the shortage of human blood.
• On the basis of source, the Middle East & Africa artificial blood substitutes market is segmented into human blood, animal blood, microorganism based recombinant HB, synthetic polymers and stem cells. In 2021, the animal blood segment is expected to dominate the artificial blood substitutes market due to availability of ample amount of source to produce artificial blood.
• On the basis of application, the Middle East & Africa artificial blood substitutes market is segmented into cardiovascular diseases, malignant neoplasma, injuries, neonatal conditions, organ transplant and maternal condition. In 2021, the injuries segment is expected to dominate the artificial blood substitutes market due to rising incidence of injuries, road accidents and others and high demand for artificial blood to treat them.
• On the basis of end user, the Middle East & Africa artificial blood substitutes market is segmented into hospital & clinics, blood banks and others. In 2021, the hospital & clinics segment is expected to dominate the artificial blood substitutes market due to rising number of patients with various illness and growing need for blood.

Artificial blood substitutes Market Country Level Analysis

The artificial blood substitutes market is analyzed and market size information is provided by the country, product type, source, application and end user as referenced above.

The countries covered in the artificial blood substitutes market report are the South Africa, and rest of Middle East and Africa

Product type segment in South Africa country is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for blood transfusion with rising number of patients. The product type segment in Rest of Middle East and Africa is dominating market owing to limited availability of human blood to treat rising number of patients.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Artificial blood substitutes is boosting the Market Growth of Artificial blood substitutes market.

The artificial blood substitutes market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.

Competitive Landscape and Artificial blood substitutes Market Share Analysis

Artificial blood substitutes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to artificial blood substitutes market.

The major companies which are dealing in the artificial blood substitutes are  HEMARINA, Hemoglobin Oxygen Therapeutics LLC, KaloCyte, Inc., LLC “Visusmed”, European Medicines Agency, OPK Biotech LLC, NuvOx Pharma, Prolong Pharmaceuticals, LLC, Boston Therapeutics, Inc., Aurum Biosciences, OXYVITA Inc, NanoBlood LLC among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many expansion and funding are also initiated by the companies’ worldwide which are also accelerating the artificial blood substitutes market.

For instance,

• In November 2020, Hemarina published a scientific report for anti-inflammatory and antibacterial property of M 101, an oxygen transporter for the treatment of periodontitis. This study has validated the quality of M 101 molecolue, which is derived from haemoglobin of the marine lugworm.
• In June 2020, KaloCyte, Inc. received a USD 300k funding from University System of Maryland (USM) Momentum Fund for developing ErythroMer, a synthetic, bio-inspired red blood substitute. This funding has helped the company in developing the ErythroMer at much faster pace.
• 2020 年 5 月，KaloCyte, Inc. 获得了美国国立卫生研究院 (NIH) 颁发的 373,000 美元小企业创新研究 (SBIR) 第一阶段拨款。这笔拨款帮助该公司推进 KaloCyte 产品进行临床前安全性和有效性测试，以备进行人体试验。

市场参与者的合作、业务扩展、奖励和认可、合资企业等策略正在增强公司在人工血液替代品市场的影响力，这也为组织的利润增长带来了好处。

SKU-64187